Rangaprasad (Ranga) Sarangarajan, Ph.D., is the Chief Scientific Officer and SVP Clinical
and Translational Sciences at BERG. He has oversight on all R&D activities and involved
in the strategic planning and implementation of activities related to pharmaceutical and
clinical developmental activities. .
Dr. Sarangarajan is the co-inventor and co-architect of the BERG Interrogative
Biology® technology; currently focused on next generation R&D innovation in the
integration of artificial intelligence based analytics, bioinformatics and RWD/RWE utility
for speeding up identification/validation of targets, tractability, drug discovery &
Dr. Sarangarajan has numerous US and international patents (granted and pending),
covering areas of the discovery platform, cancer, neurology, metabolic diseases,
diabetes, obesity and diagnostics. He has published extensively and has presented his
research in national and international medical and scientific meetings. He co-authored
and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the
role of mitochondrial function and metabolic network regulation in the etiology of cancer
as it pertains to the seminal observations made by Otto Warburg.
Dr. Sarangarajan has a B.S. in Pharmacy and graduate degree in Pharmaceutical
Sciences from the University of Cincinnati College of Pharmacy with focus on
pharmacology and toxicology. He went on to pursue post-graduate training in genetics,
molecular and cell biology for several years prior to joining Massachusetts College of
Pharmacy and Health Sciences (now MCPHS University) and served in capacity of
Arena’s business-to-business events offer a myriad of opportunities for sponsors and exhibitors to drive their businesses forward.
Our sponsorship packages help companies educate ther target market on key industry issues and spread brand awareness throughout the
If you want to discuss how we can help you generate leads and add-value to your corporate and brand image please contact:
+44 (0)20 7936 6948